Company Overview and News

0
TGXSF / Tigenix Sa 15-12B

2018-08-16 sec.gov
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTI
TGXSF

0
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer)

2018-07-31 sec.gov
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGXSF

0
TGXSF / Tigenix Sa AMENDMENT NO. 12 TO SCHEDULE 14D-9

2018-07-31 sec.gov
Amendment No. 12 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGXSF

0
Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period

2018-07-31 globenewswire
Osaka, Japan and Leuven, Belgium, July 31, 2018, 8 a.m. CEST - Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV ("TiGenix") today announced that Takeda has acquired all outstanding ordinary shares ("Ordinary Shares") (including Ordinary Shares represented by American Depositary Shares ("ADSs")) and warrants ("Warrants", and together with the Ordinary Shares and the ADSs, the "Securities") of TiGenix following the expiration of the squeeze-out period.
4502 TIG TGXSF TIG

0
Takeda rondt overname van TiGenix af na het verstrijken van de Uitkoopperiode

2018-07-31 globenewswire
Osaka, Japan en Leuven, België, 31 juli 2018, 8.00 u. CEST - Takeda Pharmaceutical Company Limited (TSE: 4502) ('Takeda') en TiGenix NV ('TiGenix') hebben vandaag aangekondigd dat Takeda alle uitstaande gewone aandelen ("Gewone aandelen") (met inbegrip van Gewone aandelen vertegenwoordigd door Amerikaanse deposito-aandelen (American Depositary Shares, 'ADS'en')) en warrants ('Warrants,' en samen met de Gewone aandelen en de Warrants, de 'Effecten') van TiGenix heeft verworven na het verstrijken van de uitkoopperiode.
4502 TIG TGXSF TIG

0
Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait

2018-07-31 globenewswire
Osaka, Japon et Louvain, Belgique, le 31 juillet 2018, 8 h 00 CEST - Takeda Pharmaceutical Company Limited (TSE : 4502) (« Takeda ») et TiGenix NV (« TiGenix ») ont annoncé aujourd'hui que Takeda a fait l'acquisition de toutes les actions ordinaires en circulation (« Actions ordinaires ») (y compris les Actions ordinaires représentées par American Depositary Shares (« ADS »)) ainsi que tous les warrants (« Warrants », qui avec les Actions ordinaires et les ADS forment les « Sécurités ») de TiGenix suite à l'expiration de la période de retrait.
4502 TIG TGXSF TIG

0
TGXSF / Tigenix Sa AMENDMENT NO. 11 TO SCHEDULE 14D-9

2018-07-27 sec.gov
Amendment No. 11 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGXSF

0
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-07-26 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
TGXSF

0
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007

2018-07-23 globenewswire
Leuven (Belgium) - July 23, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.
4502 TIG TGXSF TIG

0
TiGenix: Transparantiekennisgeving overeenkomstig Artikel 14 van de wet van 2 mei 2007

2018-07-23 globenewswire
Leuven (België) - 23 juli 2018, 22:00u CET - TiGenix NV (Euronext Brussels en Nasdaq: TIG; "TiGenix") kondigt vandaag aan dat het een transparantiekennisgeving heeft ontvangen overeenkomstig Artikel 14 van de Belgische wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt en houdende diverse bepalingen.
4502 TIG TGXSF TIG

0
TGXSF / Tigenix Sa 25

2018-07-16 sec.gov
25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGXSF

0
TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer)

2018-07-13 sec.gov
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGXSF

0
TGXSF / Tigenix Sa AMENDMENT NO. 10 TO SCHEDULE 14D-9

2018-07-13 sec.gov
Amendment No. 10 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGXSF

0
TGXSF / Tigenix Sa AMENDMENT NO. 9 TO SCHEDULE 14D-9

2018-07-07 sec.gov
Amendment No. 9 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGXSF

0
TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-07-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
TGXSF

Related Articles

REPH: Recro Pharma Analysis and Research Report

12h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

13h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

13h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 88675R109